Logo image of 22Z.DE

ZEALAND PHARMA A/S (22Z.DE) Stock Overview

Europe - FRA:22Z - DK0060257814 - Common Stock

62.32 EUR
+0.1 (+0.16%)
Last: 10/24/2025, 7:00:00 PM

22Z.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap2.87B
Revenue(TTM)9.11B
Net Income(TTM)6.68B
Shares46.12M
Float45.35M
52 Week HighN/A
52 Week LowN/A
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)12.71
PE4.9
Fwd PE21.78
Earnings (Next)11-13 2025-11-13/bmo
IPO2010-11-01
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


22Z.DE short term performance overview.The bars show the price performance of 22Z.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 4 -4 -6

22Z.DE long term performance overview.The bars show the price performance of 22Z.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of 22Z.DE is 62.32 EUR. In the past month the price increased by 5.81%.

ZEALAND PHARMA A/S / 22Z Daily stock chart

22Z.DE Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 21.49 346.25B
AMG.DE AMGEN INC 13.35 135.02B
1GILD.MI GILEAD SCIENCES INC 15.87 131.38B
GIS.DE GILEAD SCIENCES INC 15.56 128.80B
VX1.DE VERTEX PHARMACEUTICALS INC 25.3 94.65B
ARGX.BR ARGENX SE 95.12 43.57B
1AE.DE ARGENX SE 94.35 43.22B
22UA.DE BIONTECH SE-ADR N/A 21.79B
IDP.DE BIOGEN INC 9.4 19.01B
0QF.DE MODERNA INC N/A 9.03B
1MRNA.MI MODERNA INC N/A 8.85B
1EXEL.MI EXELIXIS INC 17.15 8.26B

About 22Z.DE

Company Profile

22Z logo image Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.

Company Info

ZEALAND PHARMA A/S

Sydmarken 11

Soeborg DK

Employees: 424

22Z Company Website

22Z Investor Relations

Phone: 4588773600

ZEALAND PHARMA A/S / 22Z.DE FAQ

What does ZEALAND PHARMA A/S do?

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.


What is the stock price of ZEALAND PHARMA A/S today?

The current stock price of 22Z.DE is 62.32 EUR. The price increased by 0.16% in the last trading session.


Does 22Z stock pay dividends?

22Z.DE does not pay a dividend.


What is the ChartMill rating of ZEALAND PHARMA A/S stock?

22Z.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What is the employee count for 22Z stock?

ZEALAND PHARMA A/S (22Z.DE) currently has 424 employees.


Can you provide the market cap for ZEALAND PHARMA A/S?

ZEALAND PHARMA A/S (22Z.DE) has a market capitalization of 2.87B EUR. This makes 22Z.DE a Mid Cap stock.


22Z.DE Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to 22Z.DE.


Chartmill TA Rating
Chartmill Setup Rating

22Z.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to 22Z.DE. 22Z.DE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

22Z.DE Financial Highlights

Over the last trailing twelve months 22Z.DE reported a non-GAAP Earnings per Share(EPS) of 12.71. The EPS increased by 921.54% compared to the year before.


Industry RankSector Rank
PM (TTM) 73.34%
ROA 38.89%
ROE 42.8%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%2404.28%
Sales Q2Q%26527.65%
EPS 1Y (TTM)921.54%
Revenue 1Y (TTM)2375.69%

22Z.DE Forecast & Estimates

24 analysts have analysed 22Z.DE and the average price target is 109.28 EUR. This implies a price increase of 75.36% is expected in the next year compared to the current price of 62.32.

For the next year, analysts expect an EPS growth of 638.53% and a revenue growth 11614.8% for 22Z.DE


Analysts
Analysts85
Price Target109.28 (75.35%)
EPS Next Y638.53%
Revenue Next Year11614.8%

22Z.DE Ownership

Ownership
Inst Owners48.71%
Ins Owners0.32%
Short Float %N/A
Short RatioN/A